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Abstract The sirtuin family comprises seven NAD+-
dependent deacetylases which control the overall health of
organisms through the regulation of pleiotropic metabolic
pathways. Sirtuins are important modulators of adipose
tissue metabolism and their expression is higher in lean than
obese subjects. At present, the role of sirtuins in adipose-
derived stem cells has not been investigated yet. Therefore,
in this study, we evaluated the expression of the complete
panel of sirtuins in adipose-derived stem cells isolated from
both subcutaneous and visceral fat of non-obese and obese
subjects. We aimed at investigating the influence of obesity
on sirtuins’ levels, their role in obesity-associated inflam-
mation, and the relationship with the peroxisome
proliferator-activated receptor delta, which also plays
functions in adipose tissue metabolism. The mRNA levels
in the four types of adipose-derived stem cells were eval-
uated by quantitative polymerase chain reaction, in
untreated cells and also after 8 h of hypoxia exposure.
Correlations among sirtuins’ expression and clinical and
molecular parameters were also analyzed. We found that
sirtuin1–6 exhibited significant higher mRNA expression in
visceral adipose-derived stem cells compared to
subcutaneous adipose-derived stem cells of non-obese
subjects. Sirtuin1–6 levels were markedly reduced in visc-
eral adipose-derived stem cells of obese patients. Sirtuins’
expression in visceral adipose-derived stem cells correlated
negatively with body mass index and C-reactive protein and
positively with peroxisome proliferator-activated receptor
delta. Finally, only in the visceral adipose-derived stem
cells of obese patients hypoxia-induced mRNA expression
of all of the sirtuins. Our results highlight that sirtuins’
levels in adipose-derived stem cells are consistent with
protective effects against visceral obesity and inflammation,
and suggest a transcriptional mechanism through which
acute hypoxia up-regulates sirtuins in the visceral adipose-
derived stem cells of obese patients.
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Introduction
Sirtuins (SIRTs) are NAD+-dependent class III histone
deacetylases [1], which play important roles in modulating
metabolic processes, are central to the control of energy
homeostasis and deeply involved in adipose tissue (AT)
metabolism [2]. SIRT1 is an important modulator of AT
differentiation and remodeling. Indeed, SIRT1 inhibits
adipogenesis and promotes fat mobilization by repressing
activity of the peroxisome proliferator-activated receptor
(PPAR) γ [3], induces browning of white AT promoting
energy expenditure over energy storage [4], activates lipo-
lysis [5], improves insulin signaling [6], and increases the
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expression of adiponectin [7], which is inversely correlated
with adiposity. Accordingly, the mRNA levels of SIRT1 are
suppressed in AT of obese compared to normal-weight
subjects [8, 9]. Although SIRT1 is the best known member
of the family, the knowledge of the functions of the other
less-described isoforms in AT is rapidly improving. SIRT2
has been shown to promote lipolysis and suppress adipocyte
differentiation and adipogenesis through the inhibition of
PPARγ [10, 11]; SIRT3 controls thermogenesis in brown
AT, and its reduction correlates with obesity [12]; SIRT4
coordinates the balance between lipid synthesis and cata-
bolism [13]; finally, SIRT6 has been shown to inhibit tri-
glyceride biosynthesis [14].
Functions of peroxisome proliferator-activated receptor
delta (PPARδ) in AT metabolism and weight control have
also been uncovered. Indeed, PPARδ enhances fatty acid
oxidation and energy uncoupling in AT, protects against diet-
induced obesity and improves insulin sensitivity [15, 16].
The obese AT dysfunction is in part due to its hypoxic
microenvironment and low-grade chronic inflammation
[17]. SIRT1 appears to be protective from obesity-induced
inflammation, as its reduction causes macrophage recruit-
ment and AT inflammation during chronic high-fat feeding.
Consistently, SIRT1 expression negatively correlates with
AT macrophage content in lean and obese subjects [18].
Moreover, SIRT1 can repress inflammatory gene expression
in both adipocytes and macrophages [6, 19]. Collectively,
the above mentioned data suggest a decisive role of SIRTs
against metabolic derangements and inflammation in
obesity.
Recently, we analyzed the features of the adipose-
derived stem cells (ASC), multipotent mesenchymal cells
isolated from the stromal vascular fraction of the AT [20],
and their contribution to obesity-associated inflammation
[21, 22]. To date, there are no data on the role of SIRTs in
ASC. Therefore, in this study we evaluated the expression
of the seven mammalian SIRTs in both subcutaneous and
visceral ASC from non-obese and obese subjects and
highlighted their modulation in obesity. Moreover, the role
of SIRTs in obesity-related inflammation as well as the
interplay with PPARδ were shown.
Materials and methods
Patients’ enrollment and ASC isolation and culture
ASC were obtained from both subcutaneous and
visceral AT (SAT and VAT, respectively) of 12 individuals,
4 non-obese (2 males and 2 females, body mass index
(BMI) < 30 kg/m2) and 8 obese (2 males and 6 females,
BMI > 30 kg/m2). BMI, fasting plasma glucose (FPG),
fasting insulin, glycated hemoglobin (HbA1c), total
cholesterol, high density lipoprotein (HDL)-cholesterol,
triglycerides, fibrinogen and C-reactive protein (CRP) were
recorded. SAT and VAT specimens were obtained as pre-
viously described [22]. Tissues were digested and the col-
lected cells plated in complete Dulbecco's modified Eagle's
medium [21]. In the experiments described below, ASC
were usually used at the 5th passage of in vitro culture. The
study was approved by the Institutional Review Board of
the Policlinico Umberto I in Rome, and was compliant with
Helsinki Declaration. The patients gave their informed
consent before the surgical procedure.
Cell culture in hypoxic conditions
To evaluate cell behavior during oxygen deprivation, the
culture plates were incubated for 8 h in a hypoxia chamber
(Billups-Rothenberg, Del Mar, CA) flushed with an atmo-
sphere containing 1 % oxygen, 5 % CO2 and balanced with
nitrogen, as previously described in detail [22].
Quantitative PCR analysis
The mRNA expression level in the four types of ASC, cul-
tured both in normoxic conditions and after exposure to
hypoxia, was evaluated using TaqMan Array Microfluidic
Cards designed with a purposely chosen panel of genes
through the ABI Prism 7900HT Fast Real-Time PCR System
Detector (Applied Biosystems, Foster City, CA) according to
the manufacturer’s default cycling conditions. The primer/
probe sets used were as follows: SIRT1, Hs01009005_m1;
SIRT2, Hs00247263_m1; SIRT3, Hs00202030_m1; SIRT4,
Hs00202033_m1; SIRT5, Hs00202043_m1; SIRT6, Hs0021
3036_m1; SIRT7, Hs00213029_m1; 18S, Hs99999901_s1.
Relative quantitation of the SIRTs’ gene expression was per-
formed using the 2−ΔΔCt method, using the average of the four
samples of subcutaneous ASC from non-obese subjects in
basal conditions as calibrator. Human 18S ribosomal RNA
was used as endogenous reference gene.
Statistical analysis
Data were analyzed by GraphPad Prism v5.01 (GraphPad
Software, San Diego, CA) and are presented as means ±
SEM. The paired t-test was used to evaluate the effect of
hypoxic treatment with respect to untreated cells and to
analyze the differences of clinical parameters in the two
groups of individuals. One-way ANOVA with Bonferroni
post-test for multiple comparisons was used to compare the
ASC populations. Spearman correlation coefficient test was
used to analyze the relationships between variables.
P values< 0.05 were considered significant.
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Results
Clinical and anthropometric characteristics of the
subjects
The characteristics of the patients are shown in Table 1.
There was a significant difference in BMI between the two
groups. Non-obese donors showed normal levels of the
blood parameters evaluated. Differently, the obese patients
had a mild alteration of glucose metabolism, but no diabetic
subjects were involved in the study, as evidenced from the
plasma levels of HbA1c. A mild dyslipidemia was also
observed in obese, together with a significant increase of
CRP blood values, compared to non-obese individuals.
Visceral ASC of non-obese subjects express high basal
mRNA levels of SIRT1–6
We analyzed the basal expression of the seven SIRTs in
both subcutaneous and visceral ASC isolated from non-
obese and obese subjects. The evaluation and comparison of
the ASC subpopulations from non-obese donors (nS-ASC
vs. nV-ASC) showed that visceral ASC expressed sig-
nificantly higher levels of SIRT1–6 compared to sub-
cutaneous ASC (Fig. 1a). Differently, the ASC isolated
from obese patients (obS-ASC vs. obV-ASC) did not reveal
any significant differences in SIRTs’ expression, although
the visceral adipose-derived stem cells of obese patients
(obV-ASC) showed a trend to lower expression of SIRT1-6
(Fig. 1b). SIRT7 had comparable basal expression in ASC
of the two different AT sites, both in non-obese and obese
subjects.
SIRT1–6 expression levels are markedly reduced in the
obV-ASC
The above findings clearly indicate that obesity influences
the expression of SIRTs in ASC. Further analysis of the
data, performed to compare the SIRTs’ expression in obese
vs. non-obese subjects, highlighted indeed that the levels of
SIRT1-6 were substantially lower in the obV-ASC than in
the nV-ASC (Fig. 1d). Differently, the nS and obS-ASC had
comparable levels of SIRT1–6, although the obS-ASC
presented a non-significant trend to higher expression
(Fig. 1c). Irrespective of the metabolic status of the donor,
SIRT7 showed similar expression in both types of ASC.
SIRTs’ mRNA expression correlates negatively with
BMI and CRP and positively with PPARδ in visceral
ASC
Possible correlations among the mRNA expression of the
seven SIRTs and clinical parameters listed in Table 1 were
evaluated on the whole cohort of individuals. The analysis
unveiled significant inverse correlations between SIRT1–6
mRNA expression and BMI or CRP in visceral ASC
(Table 2), whereas no association was evident in sub-
cutaneous ASC (data not shown). As reported in our pre-
vious paper [22], the basal mRNA levels of PPARδ and
PPARγ were analyzed in the same four ASC subpopula-
tions in which SIRTs’ expression was evaluated, showing
that the level of PPARδ was substantially lower in the obV-
ASC than in the nV-ASC. Table 3 shows significant posi-
tive correlations among the mRNA expression of SIRT1–6
and PPARδ in visceral ASC, whereas no correlation was
found among SIRTs and PPARγ.
Hypoxia induces the SIRTs’ mRNA expression only in
the obV-ASC
As previously shown [22], we evaluated the possible con-
tribution of the four ASC subpopulations to obesity-
associated inflammation, showing that the mRNA levels
of the inflammation-related genes NF-kB and NF-kB tran-
scriptional targets were up-regulated in the obV-ASC upon
8 h of hypoxia exposure. In the present study, we tested
whether SIRTs could also represent a possible target for
hypoxic adaptation in ASC. Figure 2a shows that 8 h of
oxygen deprivation did not induce significant changes of the
SIRTs’ expression in the two types of subcutaneous ASC
compared to the basal value (indicated by a horizontal line
in the graph). On the contrary, the subpopulations of visc-
eral ASC displayed a significant modulation of several
SIRT genes (Fig. 2b). In particular, all of the SIRTs were
up-regulated in the obV-ASC, whereas SIRT5 and 6 were
down-regulated and no significant change was observed for
Table 1 Clinical characteristics of non-obese and obese patients
Non-obese Obese P-value
Age (years) 52.00± 4.80 40.40± 1.14 0.178
BMI (Kg/m2) 25.62± 0.55 44.66± 4.64 0.017*
FPG (mg/100 ml) 90.75± 1.75 95.62± 7.25 0.654
Insulin (µUI/ml) 16.85± 3.28 24.11± 2.99 0.163
HbA1c (%) 4.70± 0.43 5.46± 0.28 0.161
Total-C (mg/100 ml) 198.00± 3.67 209.00± 15.74 0.640
HDL-C (mg/100 ml) 52.25± 4.55 50.87± 2.52 0.770
Triglycerides (mg/100 ml) 129.00± 13.15 159.37± 19.17 0.322
Fibrinogen (mg/100 ml) 364.25± 44.95 449.75± 34.97 0.177
CRP (mg/100 ml) 0.37± 0.11 1.23± 0.19 0.012*
Values are expressed as the mean± SEM
BMI body mass index, FPG fasting plasma glucose, HbA1c glycated
hemoglobin, Total-C total cholesterol, HDL-C high density lipoprotein
cholesterol, CRP C-reactive protein
*P< 0.05 of obese vs. non-obese individuals
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SIRT1, 2, 3, 4 and 7 in the nV-ASC. However, after 8 h of
oxygen deprivation, the levels of SIRT1–6 in the obV-ASC
were significantly lower compared to those observed in the
nV-ASC (Fig. 3).
Discussion
At present, there is no information regarding the expression
of the complete panel of SIRTs in the ASC of the human fat
Fig. 1 Comparison between the constitutive expression level of each
SIRT in subcutaneous vs. visceral ASC and in obese vs. non-obese indi-
viduals. Q-PCR showing mRNA expression of the seven SIRTs in the four
subpopulations of ASC. The comparison between the expression level of
each gene in the subcutaneous and visceral ASC of a the non-obese (nS-
vs. nV-ASC) and b obese (obS- vs. obV-ASC) individuals is shown. The
same data were further analyzed to compare the SIRTs’ expression in c the
two types of subcutaneous ASC (nS- vs. obS-ASC) and d visceral ASC
(nV- vs. obV-ASC) of non-obese and obese subjects. The amount of each
SIRT gene, normalized to the endogenous reference gene 18S and relative
to the average of the four nS-ASC samples in basal conditions chosen as
calibrator, was determined by the 2−ΔΔCt method. The data are expressed as
the mean± SEM. £P< 0.05, ££P< 0.01 and £££P< 0.001 of nS-ASC vs.
nV-ASC and $$P< 0.01 and $$$P< 0.001 of nV-ASC vs. obV-ASC
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depots. To address this issue, we investigated the mRNA
expression levels of SIRTs in ASC isolated from SAT and
VAT of non-obese and obese subjects. Our data showed very
high levels of SIRT1–6 in the nV-ASC compared to the nS-
ASC which could be related to the different metabolic
activities of the two fat depots. It is consistent that the SIRTs’
expression is higher in the nV-ASC, as they control pleio-
tropic metabolic pathways that increase the overall health of
organisms [3–14]. Indeed, while SAT is deputed to store the
excess of energy intake, such as free fatty acids (FFA) and
glycerol that are deposited in the form of triglycerides, VAT
has a larger effect on metabolism. VAT has a greater number
of large adipocytes, which are more sensitive to lipolysis and
insulin-resistant, thus contributing to the plasma FFA levels
and glucose uptake. Moreover, it is more infiltrated with
inflammatory cells and more capable of generating inflam-
matory markers, whereas has less preadipocyte differentiation
capacity than SAT. Consequently, VAT accumulation is
Table 2 Correlations among constitutive mRNA expression of SIRTs
and BMI or CRP in visceral ASC
BMI CRP
r P r P
SIRT1 −0.595 0.041* −0.677 0.016*
SIRT2 −0.564 0.050* −0.589 0.044*
SIRT3 −0.725 0.008** −0.705 0.010**
SIRT4 −0.683 0.014* −0.646 0.023*
SIRT5 −0.553 0.062 −0.790 0.002**
SIRT6 −0.725 0.008** −0.660 0.020*
SIRT7 0.119 0.712 −0.277 0.383
Values are expressed as the mean± SEM
*P< 0.05 and **P< 0.01 of BMI or CRP relative to the mRNA levels
of each SIRT
Table 3 Correlations among basal mRNA expression of SIRTs and
PPARδ or PPARγ in visceral ASC
PPARδ PPARγ
r P r P
SIRT1 0.812 0.011* −0.067 0.880
SIRT2 0.803 0.009** −0.217 0.575
SIRT3 0.728 0.031* 0.067 0.880
SIRT4 0.778 0.017* −0.050 0.912
SIRT5 0.770 0.021* 0.083 0.843
SIRT6 0.904 0.002** −0.233 0.552
SIRT7 −0.075 0.843 −0.100 0.810
Values are expressed as the mean± SEM.
*P< 0.05 and **P< 0.01 of the mRNA levels of PPARδ relative to
those of each SIRT
Fig. 2 Low oxygen determines up-regulation of the mRNA expression
of SIRT1-7 compared to the basal levels in the obV-ASC. Q-PCR
showing the changes in the mRNA levels of SIRTs in a the nS- and
obS-ASC and b the nV- and obV-ASC after 8 h of oxygen deprivation.
The amount of each SIRT gene, normalized to the endogenous control
18S and relative to the average of the four nS-ASC samples in basal
conditions chosen as calibrator, was determined by the 2−ΔΔCt method.
All the values are expressed as the mean± SEM. *P< 0.05 and **P<
0.01 of the effect of hypoxia relative to each untreated control, to
which a value equal to 1 was arbitrarily assigned (horizontal lines in
the graphs). $P< 0.05 and $$P< 0.01 of nV-ASC vs. obV-ASC
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associated with increased risk for diabetes, cardiovascular
disease, hypertension and stroke [23].
The SIRTs’ activity is regulated by their ability to act as
energy sensors [1]. In fact, a low-energy status that
increases cellular levels of NAD+, such as fasting or calorie
restriction, can activate SIRTs, whereas a high-energy
status that decreases NAD+ levels, including high-fat diet,
reduces SIRT activity [24]. Consistently, several reports
showed that SIRT1 expression is higher in lean compared
to obese subjects [8, 9] and that transgenic mice over-
expressing SIRT1 or mice treated with SIRT1 activators
were protected against diet-induced obesity [25–27]. Con-
versely, AT-deletion of SIRT1 in mice fed with low-fat diet
induced similar changes in gene expression than high-fat
diet in wt mice, which showed reduced levels of SIRT1
mRNA and protein [28]. SIRT1 was reduced also in VAT
and plasma of obese subjects with severe liver steatosis
[29, 30], and negatively correlated with visceral fat areas
[31]. Other studies showed that under calorie restriction
SIRT1, 2 and 3 levels in AT increased, as well as SIRT1 in
plasma [12, 32–34], whereas decrease of SIRT2 in VAT
and SIRT4 in plasma was observed in obese [35, 36]. In
agreement with all these findings, our results showed a
strong reduction of the SIRTs’ expression in the obV-ASC
compared to the nV-ASC. Moreover, the observation that
only in visceral ASC the mRNA levels of SIRT1–6
inversely correlated with BMI suggests a close link among
SIRTs’ expression and body fat amount and distribution.
Accordingly, the inverse correlation between the plasma
CRP levels of all of the individuals analyzed and the
SIRTs’ expression in the respective visceral ASC suggests
that the protective effects of SIRTs concern also the
obesity-associated inflammation, which is a peculiar fea-
ture of visceral obesity. Several reports showed that SIRT1,
2 and 6 exert anti-inflammatory effects through the inhi-
bition of NF-kB signaling mediated by their deacetylase
activity [6, 37–40]. In contrast, other studies described that
SIRT1, 2 and 6 may be positive regulators of inflammatory
processes [41–44]. It was suggested that NF-kB up-reg-
ulates SIRT1 at transcriptional level through the binding to
a consensus NF-kB binding site on the promoter of SIRT1,
also under inflammatory conditions [45, 46]. Interestingly,
in addition to SIRT1, also SIRT2, 4 and 7 have potential
NF-kB binding sites on their promoters (based on
SABiosciences’ proprietary DECODE database). In a
recent study, performed on the same four ASC sub-
populations used here, we analyzed the effects of hypoxia
on the NF-kB pathway, highlighting that the obV-ASC
exhibited hyper-responsiveness to hypoxia, which induced
strong NF-kB activation and NF-kB target genes’ expres-
sion, maximal after 2 and 8 h of oxygen deprivation,
respectively [22]. In the present work, we evaluated whe-
ther SIRT genes could play a role in the NF-kB-mediated
increase in inflammatory response. Actually, the previously
observed NF-kB activation is consistent with the cell-
specific up-regulation of the mRNA levels of all of the
SIRTs observed after 8 h of hypoxia exposure solely in the
obV-ASC, that we report here. Therefore, overall, our
results support a transcriptional action of NF-kB on the
SIRT genes in the obV-ASC. In agreement with Zhang
et al., who suggested that SIRT1 up-regulation by NF-kB
could be a ubiquitous auto-protective response of the cells
to inflammatory events [45], we hypothesize that a similar
regulatory mechanism may also exist in the obV-ASC.
Indeed, the hypoxia-induced SIRTs’ increase may result in
a negative feedback loop controlling NF-kB signaling
through the SIRTs’ deacetylase activity to attenuate the
deregulated inflammatory response of the obV-ASC. This
notion is supported by the observation that the other three
ASC subpopulations, that did not show NF-kB activation
after 2 h of hypoxia exposure [22], do not exhibit even the
enhancement of the SIRTs’ expression. However, it should
be noted that despite acute hypoxia increases the SIRTs’
expression in the obV-ASC, the levels remained sig-
nificantly lower than those of the nV-ASC. Consistently,
the findings that the obV-ASC also constitutively expressed
significantly lower levels of SIRT genes when compared to
the nV-ASC, clearly indicate that in the obV-ASC, which
underwent chronic exposition to an altered and hypoxia-
remodeled AT microenvironment, the above proposed
Fig. 3 Levels of SIRTs in the nV- and obV-ASC after hypoxia
exposure. Q-PCR showing the mRNA expression of SIRTs in the nV-
and obV-ASC after 8 h of hypoxia exposure (nV H and obV H,
respectively). The amount of each SIRT gene, normalized to the
endogenous control 18S and relative to the average of the four nS-ASC
samples in basal conditions chosen as calibrator, was determined by
the 2−ΔΔCt method. The data are expressed as the mean± SEM.
$$P< 0.01 and $$$P< 0.001 of nV-ASC vs. obV-ASC
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auto-protective mechanism against inflammatory events is
prevented.
In AT, PPARγ plays known functions such as adipocyte
differentiation and up-regulation of genes involved in
lipogenesis and triglyceride storage [47]. Consistently, we
observed an inverse trend between PPARγ and SIRTs’
expression. However, several effects of PPARδ in AT,
opposite to those of PPARγ, have been also elucidated.
Interestingly, like SIRTs, PPARδ is able to protect against
obesity [15, 16]. In agreement with these findings, our
results showed the existence of a positive relationship
between PPARδ and SIRTs in visceral ASC suggesting that
the protective effects of SIRTs may involve PPARδ.
Accordingly, it has been recently shown that PPARδ up-
regulates SIRT1 expression at the transcriptional level [48,
49]. These findings clearly show another possible regulator
of SIRTs in AT.
Although, in our study, the assessment of SIRTs’
expression was performed only at mRNA level, the results
have high reproducibility and strong statistical significance.
In conclusion, this study for the first time analyzes the
expression of the seven SIRTs in the ASC of both sub-
cutaneous and visceral human fat depots of non-obese and
obese subjects. The results highlight the influence of obesity
on the SIRTs’ expression, a possible mechanism through
which SIRTs are involved in obesity-associated inflamma-
tion, as well as the interplay with PPARδ. Importantly,
these findings also indicate interesting novel pathophysio-
logical frameworks for SIRTs to explore in ASC.
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